MIRIKIZUMAB, THE FIRST IL-23P19 INHIBITOR TO DEMONSTRATE SUSTAINED EFFICACY THROUGH 1 YEAR IN PEDIATRIC MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY FINDINGS FROM SHINE-2 (UEGW 2026) - Sep 24, 2026 - Abstract #LB11; Pres time: Oct 19, 2026; 10:00 AM - 11:00 AM; Location: Room UEG Forum; "Full abstract will be published on the day of presentation"
Clinical • Late-breaking abstract • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pediatrics • Ulcerative Colitis
|
|
D. Turner 1; A. Bousvaros 2; A. Griffiths 3; J.S Hyams 4; N. Singh 5; T. Holzkämper 5; W.J Komocsar 5; N. Morris 5; Y. Otani 5; S. Budree 5; R.N Baldassano 6; R.K Russell 7; M.C. Dubinsky 8
|